Drug Watch

Latest News

Abeona Submits Biologics License Application to FDA for EB-101
Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.

Izokibep Fails in Phase 2b/3 Hidradenitis Suppurativa Trial
Izokibep Fails in Phase 2b/3 Hidradenitis Suppurativa Trial

September 12th 2023

Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older
Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older

September 12th 2023

Replimune and Incyte to Collaborate on Clinical Trial to Study RP1 in Combination With INCB99280 for CSCC
Replimune and Incyte to Collaborate on Clinical Trial to Study RP1 in Combination With INCB99280 for CSCC

August 1st 2023

Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma
Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

July 27th 2023

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection

More News

© 2023 MJH Life Sciences

All rights reserved.